December 2022 – Page 131 – 1stOncology™: Cancer Intelligence Service

Lixte – Dedicated to creating better treatments for cancer

On December 6, 2022 Lixte Biotechnology presented its corporate presenetation (Presentation, Lixte Biotechnology, DEC 6, 2022, View Source [SID1234624844]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

iBio Announces Proposed Underwritten Public Offering

On December 6, 2022 iBio, Inc. (NYSEA: IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, reported that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and Series A and Series B warrants to purchase shares of common stock in an underwritten public offering (Press release, iBioPharma, DEC 6, 2022, View Source [SID1234624843]). In connection with the offering, the Company also intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less underwriting discounts and commissions.

H.C. Wainwright & Co. is acting as sole book-running manager for the proposed public offering.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The Company intends to use the net proceeds from the offering primarily for operating costs, including for research and development and other trial preparation expenses in addition to working capital needs and for other general corporate purposes, which may include retention and severance payments to certain of our employees or former employees and principal payments pursuant to the terms of its amended Credit Agreement.

The securities described above are being offered by iBio pursuant to a shelf registration statement on Form S-3 (File No. 333-250973) that was previously filed with the Securities and Exchange Commission (the "SEC") on November 25, 2020 and became effective on December 7, 2020. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the preliminary prospectus supplement and the accompanying base prospectus, when available, may also be obtained by contacting H.C. Wainwright & Co., LLC, at 430 Park Ave., New York, New York 10022, by telephone at (212) 856-5711, or by email at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

iBio to Participate in the JMP Securities Hematology and Oncology Summit

On December 6, 2022 iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, reported that its Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 1:20 p.m. Eastern Time (Press release, iBioPharma, DEC 6, 2022, View Source [SID1234624842]).

The fireside chat will be broadcast live and archived on the Company’s website at www.ibioinc.com under "News & Events" in the Investors section.

Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy

On December 6, 2022 Caris Life Sciences(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, reported a strategic collaboration to advance clinical development of Hummingbird Bioscience’s anti-HER3 therapy, HMBD-001 (Press release, Hummingbird Bioscience, DEC 6, 2022, View Source [SID1234624841]).

Hummingbird Bioscience, a clinical-stage biotechnology company, uses their proprietary and differentiated technologies to drug clinically-validated targets which have previously been elusive. Their most advanced program, HMBD-001, is a HER3 antibody that uniquely targets an epitope on the critical dimerization interface. HER3 is a member of the epidermal growth factor receptor (EGFR) family, known to be important in tumor progression and metastasis. Unlike earlier generations of HER3 antibodies, HMBD-001 blocks both ligand-dependent and ligand-independent signaling, eliciting potent anti-tumor effects. Leveraging Caris’ extensive real-world clinico-genomic database to support clinical trial design, Hummingbird Bioscience will be better able to prospectively identify patients with molecular biomarkers that are potentially associated with response to HMBD-001.

"Caris’ partnership with Hummingbird Bioscience aligns with our goal of leveraging molecular and clinical data to power and accelerate the development of precision therapies," said Brian Lamon, Ph.D., Chief Business Officer at Caris Life Sciences. "Our partnership will help evaluate biomarkers to better understand the clinical utility for this novel therapy, drive patient recruitment and clinical trial access, and may ultimately provide new treatment alternatives and options to patients who are not responding to current therapies."

"With our proprietary technologies, Hummingbird Bioscience discovers and develops unique biotherapeutics against challenging oncology and autoimmune targets. To ensure that these novel therapies succeed, we must conduct intelligent and focused clinical trials on patients who are likely to benefit the most," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer and co-founder at Hummingbird Bioscience. "As a data-driven company, we understand the value of using large cohorts of molecular and clinical information to gain a deeper understanding of the patients who may respond to this exciting new therapy and track their response. We are excited by the potential of this partnership, and we look forward to better, more efficient clinical development with access to Caris’ vast amount of real-world data and state-of-the-art comprehensive profiling technologies."

Since the launch of its molecular profiling service in 2009, Caris has amassed molecular data on more than 400,000 patients and real-world clinical outcomes on more than 275,000 patients. Caris’ state-of-the-art sequencing laboratories are among the most advanced in the world, which allows the company to perform whole exome DNA sequencing and whole transcriptome RNA sequencing on every patient. Caris’ data-driven, molecular insights are changing the landscape of precision medicine with actionable insights from retrospective, epidemiologic and real-time molecular data to enhance research and commercial activities.

Genomic Testing Cooperative to Present Data at the American Society of Hematology Meeting on New Applications of its Proprietary Tests that Combine Transcriptome Data Obtained from Tissue or Liquid biopsies with Machine Learning

On December 6, 2022 Genomic Testing Cooperative, LCA (GTC) announced the presentation of four innovative studies at the annual American Society of Hematology (ASH) (Free ASH Whitepaper) meeting that will be held from December 10 to 13, 2022 in New Orleans, Louisiana (Press release, Genomic Testing Cooperative, DEC 6, 2022, View Source [SID1234624840]). The studies highlight and validate the value of the extended molecular profiling testing currently offered by GTC in evaluating hematologic neoplasms using DNA and RNA next generation sequencing (NGS).

GTC reports that by combining targeted transcriptome with a proprietary machine learning algorithm, they can predict which patients with advanced myelodysplastic syndrome/acute myeloid leukemia will respond to treatment with Venetoclax-based therapy. In another study, GTC demonstrates that combining targeted transcriptome with machine learning can predict which patients will develop acute graft-versus-host disease (aGVHD) not only post-transplant, but also using pre-transplant sample, which suggests that the patient’s own bone marrow microenvironment may contribute to the development of aGVHD.

GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace. Using cfRNA, GTC studies show that the cfRNA levels can be used in "liquid immunoprofiling" of hematologic neoplasms. Combining this liquid immunophenotyping with machine learning algorithms report high reliability in the differential diagnosis between various types of lymphoid neoplasms/lymphoma.

A fourth study explored the disparity in somatic mutations and outcome in primary central nervous system lymphoma between Hispanic and non-Hispanic patients.

"The work presented at ASH (Free ASH Whitepaper) reflects the commitment of GTC to be the leading diagnostic company in innovation and in advancing the science of diagnostics and biomarkers discovery, especially in hematologic neoplasms," said Dr. Maher Albitar, founder, chief executive officer and chief medical officer of GTC. "The use of RNA profiling in tissue and liquid biopsies is opening new horizons in diagnostics, especially when combined with artificial intelligence. Because of the collaborative business model adapted by GTC as a cooperative (Co-Op) company, we are able to lead in this field. The commitment of all members of the Co-Op to work closely with GTC to improve patient care and advance precision medicine made this work possible" added Dr. Albitar.

Following is a list of GTC presentations:

1) DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy. December 11, 2022: 6:00 PM-8:00 PM

2) Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA. Sunday, December 11, 2022: 6:00 PM-8:00 PM

3) Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute GVHD (aGVHD) and Overall Survival after Allogeneic HSC Transplantation. Saturday, December 10, 2022: 5:30 PM-7:30 PM

4) Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity. Saturday, December 10, 2022: 5:30 PM-7:30 PM

Please visit GTC booth #205 at the ASH (Free ASH Whitepaper) exhibit hall for more information.

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!

Month: December 2022

Lixte – Dedicated to creating better treatments for cancer

iBio Announces Proposed Underwritten Public Offering

iBio to Participate in the JMP Securities Hematology and Oncology Summit

Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy

Genomic Testing Cooperative to Present Data at the American Society of Hematology Meeting on New Applications of its Proprietary Tests that Combine Transcriptome Data Obtained from Tissue or Liquid biopsies with Machine Learning